Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we concluded that substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Nov 12, 2026
Conference · 2026-11-16
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Hi, everyone. My name is Maury Raycroft, and one of the biotech analysts at Jefferies. I'm happy to introduce and welcome Alan Ryan, the CEO of Prime Medicine. Thanks for joining us today, Alan.
Maury, thanks for having us. I appreciate being here.
And we're going to do fireside chat format, so maybe for those who are new to the story, if you can give a one-minute intro to the company.
Yeah, one minute's always tough to explain Prime Medicine. I just used up about four seconds of that. But Prime Medicine, I think about it as really a next-generation gene-editing technology. You can really think about it as the most versatile way to edit the genome. So we can do any kind of edit, any other gene-editing kind of technology can do, but then so many more different variations and things that other gene-editing technologies really can't do. So it's extremely versatile, but it's also very safe in the way we edit. So you're doing single-stranded breaks. It's a more precise way to edit. And it's a company that's now, you know, we're going towards our first approval next year. And for an ex vivo program, it's something called chronic granulomous disease. We've just announced first patient dose in our Wilson program, and we've got our alpha-1 IND now active. So we're going to get to some pretty important clinical data inflection points next year as well. And maybe just to round out the one minute, I would just say, you know, there's a lot of opportunity, Other than just the things we're focusing on today. So as we de-risk that, we think there's a lot to leverage down the road as we think about additional indications, both big and medium-sized.
Got it. Yeah, that was great. You got a lot into the minute there. And maybe starting with Wilson's, you dosed your first patient in your global phase 1-2 in October. Can you walk us through how enrollment's going for the study, how many sites are open, which countries, and how quickly you're finding the patients?
Yeah, so the first site or the first country that we said the trial was sort of good to go and was New Zealand. So that was the first geography. And then we announced the IND subsequent to that. So now we're up and running in the U.S. So we've got the site New Zealand. In the U.S., there's going to be obviously multiple sites. So there's a number that are being – I know we have a number of site initiation visits soon. So in addition to some of the sites that are already up and going, there's going to be a lot of additional sites, and then Europe as well. So it's not just a – this is a global study. We're going to have multiple sites. In terms of an update on enrollment, I mean, we announced the first patient dosed in early October. We're not going to give updates beyond that, so the next you'll hear about the program is likely when we announce the clinical data. What I can say is there's a lot of excitement from both the So from at least what I can see, I think this is a trial that's going to enroll well. This is an area where we believe there's significant unmet need and high degree of motivation or a very motivated patient population that's looking for new treatments like this to really change the course of their disease.
Got it. And you've got a lead-in observational study. How's that helping with recruitment? You already have a lot of patients lined up in the queue for dose escalation.
Yeah, so we started what we call an observational study late last year. That's a study where we can go and really genotype these patients and observe. So through that, we've identified a significant number of H1069Q mutated patients, which are the Wilson disease patients that are going to be eligible for this trial. As we get the sites up and running where we've identified these patients, those will definitely be patients that can either come into the initial trial. Because remember, this is a dose escalation, call it at least a few cohorts. So, you know, just thinking about, like, a three patient per cohort in and around there, you're looking at, you know, just a nine patients call it, you know, can always expand from there. But as we think about expanding this beyond the initial cohorts, we think there's a lot of patients out there to go after, both in the U.S. and ex-U.S.
And for the initial nine patients, you basically, do you have line of sight to those patients then, or? Sure.
It's not like we're going to screen as we go from patient to patient, but I'd say there's a lot of patients that have been identified or sites that have identified. You still go through the process for this study to actually go through that screening and get that patient into the study. So I wouldn't say we've got nine patients identified today that we know we're going to enroll, but I would say there's a lot more than that likely than investigators have. I don't see enrollment to the study being an issue.
Got it. Okay. And is there a standard 30-day safety monitoring for a dose-limiting toxicity window between patients, or is there a longer safety observation period?
No, there's not a longer safety period than that. It's a little nuanced, but you can have different staggering in different geographies. So the U.S. is pretty standardized now, but other geographies can be shorter. So I'd say that's sort of the minimum amount of time between cohorts, but if you're just talking about the U.S., But there's kind of shorter potential staggers as you look at SUS as well.
Got it. And so if you think about that, you've already dosed the first patient in October. Have you dosed that second patient?
Again, we're not going to give the update. So if we update the second patient, then we're going to be updating the third, fourth, fifth. And for me, I think it's a trial, again, that I think is going to enroll very well. We're guiding to data in 2027. We expect to provide a pretty fulsome data update when that occurs. And that's, you know, essentially what we're going to say about enrollment from here on in.
Understood. And for that safety monitoring window, I guess, what are you looking for there? Is it liver enzymes, inflammatory markers?
Yeah, so if you think about LNPs that have gone into humans, especially as you think about, you know, in and around the dose levels that we're talking about, for liver-directed LNPs especially, Especially, things that we've seen are increased, not that we've seen as in our LNP, that the LNP that we've seen across different LNPs that have gone into the clinic are increases in liver function tests. So that's something you're definitely going to monitor for. Typically, you'd see that early on, but there's definitely been instances where that's happened kind of in the later part, or you've seen it even after 30 days. And those could be, maybe, are less likely to be LNP-related and more likely to be other reasons that are causing those. We'll look at inflammatory markers. Again, things you'd expect to see elevated very early after dosing, not something you'd expect to see kind of later in that time window. You could look at coagulation markers and other things as well. So, again, you expect with LNPs typically to see, if you're going to see tox, you're going to see it early. Thankfully, in our GLP tox studies, we're able to dose much higher than where we're dosing in the clinical study, and really think we've got a very wide therapeutic index here. Obviously, we have to prove that out in the clinic, but at least what we've seen preclinically.
Got it. And how close to an active dose is your first dose? I guess you mentioned possibly starting below 0.4 mg per keg and escalating toward about 0.8 mg per keg, Which are the ranges that normalize copper metabolism in pet and mice in a mouse model? Are you expecting a biological signal from core one, or is the plan to establish safety and work up from there?
Yeah, I mean, usually the FDA wants you to go in, you know, if your safety margins allow for it, with a biologically active dose. It can be a low-level activity, but that has some activity, especially when you're thinking about a once-and-done therapy. So even at the lowest dose, we'd expect some level of editing. Again, that could be a low level of editing, so you're not going to be clearly at your optimal biologic dose. Whether you'll be able to pick that up on a radio-label PET scan or some of these other markers, we'll have to wait and see if there's enough editing to see that. As we start to get into the second dose, if the preclinical data predicts, is really predictive and translates well to the clinical data, then it's possible we'll start to see some efficacy, some real efficacy in the second dose. I mean, at that second dose level, if we look at our preclinical data. You know, it's getting to a pretty active dose. As we go to that next dose level, we should be at a pretty high level of editing efficiency where we expect to see a lot of activity. But again, you know, that doesn't always translate exactly as you go from a mouse, you know, a mouse to a monkey, then a mouse monkey, and then into a human. And so, again, you could always be surprised both ways in terms of kind of what dose levels are ultimately effective.
And does the patient background matter, I guess, where you treat the H1069Q homozygates and compound heterozygates at the same initial dose levels?
Yeah, so we can treat both in this study. I like the idea of really looking at the homozygous patients because, you know, you have the potential to have efficacy at a potentially lower dose. That might not be the case. It might be equivalent, but we'll have to wait and see. So I think once you establish efficacy there, then in what's called a compound heterozygote, so homozygous patient, both patients are going to have the same, they have the same mutation of both alleles, but some of these patients can be compound heterozygote. So they might have the 1069Q mutation in one allele, then they'll have a different Wilson disease mutation in the other allele, and together that's Wilson disease, right, because they have two mutations within that gene that are both pathogenic. What we've shown preclinically is we actually have very strong data, not just in the homozygous animals, but also in the compound heterozygous models as well. But it is a good question. Clinically, is the dose that we need for both those going to be the same? Again, we'll have to wait and see as we go. It might be for a compound, you need to be slightly higher. It could be one dose is going to be the right dose for all of these patients. That's something we'll be testing out clinically.
Got it. Okay. And what would make the first Wilson's update a success? Do you need to finish all three planned dose cohorts, or if you see a signal in the first six patients across the two cohorts, would you do an update based on that?
Yeah, I think we're planning to do an update once we have the full dose escalation complete. I like the idea of a full update once we have all the data. I think having at least three cohorts, three patients each, really tells you where you are in terms of the dose response curve. If you look at the middle dose, even if you see great efficacy there, let's see what we get at a dose higher, right? I would still expect to see even more editing, potentially better efficacy at a higher dose. For these patients, even just getting them to what would be like a heterozygote level, so I talked about compound heterozygotes before, so those are two mutated. Both genes mutated. A heterozygote has just one mutation in one allele, the other is completely fine. So they can make... Normal protein as well. And in a heterozygote person, they actually don't develop disease. They do have impaired copper metabolism. So if you look at their copper metabolism level, and you can do this by measuring what we call radiolabeled copper PET studies, and you can see that a Wilson disease patient is going to have very high levels of copper. So you kind of measure this out at about 20, 24 hours, you'll see very high concentration of copper in the liver, where a wild-type normal person will sort of have a flat line, and you don't see that copper accumulate, where a heterozygote will have some accumulation, and that'll really flatten out, but very different from what you see in a Wilson disease patient. So even if we can convert that disease patient to a essentially heterozygote patient, that should effectively or at least genetically cure that patient of disease.
Got it. And, uh... One of the secondary endpoints is the ability to discontinue standard of care. Can you walk us through what the protocol says happens after the first post-dose PET scan at six weeks to eight weeks? And is getting PET back to a heterozygous level of copper metabolism, is that what you're looking for?
Yeah, so... You know, in terms of the radio-label copper pad, so again, if we can get to that heterozygous level, like you said, that would absolutely be, we think, in the space where you could take a patient off standard of care, and they should have a normalized level of serum copper and essentially not be at risk of developing further disease progression. Um, and I think there are, um... You know, and again, as you think about standard of care, there are different criteria that we would look at that investigators can look at. Ultimately, it's investigator discretion. So there are different criteria listed that can be used to determine when to remove and how to remove standard of care. But again, in the end, it is going to be investigator discretion on when and how that is done.
Got it. And what role does fecal and urinary copper play in that decision?
Yeah, I mean, we're going to be measuring urinary copper. We'll be measuring seroplasmin levels. We've actually chosen not to measure fecal copper, just the difficulty in collecting that for these studies. So, look, I do think about it potentially as a mosaic as you're looking at all these different endpoints. But our real hope is on the radiolabel copper PET studies, you know, we're going to be able to... image of these patients and really see if copper metabolism has been improved or restored. And in some ways, if that's the case, then all of these other measures should start to correlate with that.
Got it. And there's a Danish copper PET study. Is that the benchmark that you're using? And does that set the measure that you used in your protocol?
Yeah, so that is the benchmark that we're using in a sense. So we've worked a lot with that investigator really to develop the way we're doing our radiolabeled copper PET studies. This is really a Dr. Sandahl out of Denmark who's done probably the greatest number of radiolabeled copper PET studies within these patients. Every time you do it, when I say standardized, it's a light measure. You're really measuring the brightness on these PET studies on kind of how much copper is within that liver. So as we do those studies, we'll sort of standardize. But what's going to allow us to see the difference, so he was just doing these studies on what we call normal patients or wild-type people versus heterozygates versus Wilson disease patients. What we're actually doing is a before and an after. So you'll see a pre-dose copper PET study, and then we'll be comparing that six to eight weeks post-dose. So we can do, you know, interpatient comparisons. That's really going to tell us kind of where we are and lead to how we kind of standardize this across patients. If we talk to Dr. Sandahl, he'll say, if you just show me a gallbladder at an hour and a half, I can tell you if that person has disease or not. So he's like, all I need to see is that gallbladder at an hour and a half, and I can tell you if that copper metabolism is there as normal. Interesting.
Are there specific thresholds that you want to see then?
There are. I mean, I think as we look at that data, and I encourage people to go and look at that study, and I think as you look at those thresholds, there are pretty tight error bars around what a diseased patient looks like and then between where a heterozygote and then a normal are. So, you know, if we're seeing values and improvements as to converting a disease patient to closer again to the levels that you get with a heterozygote or wild type, then we know this drug is really doing what it's supposed to do.
Right. And you've described targeting patients with moderate Wilson's disease. How do you define moderate disease in the protocol, and what proportion of the Wilson's population will fall into that group?
Yeah, I don't think, I don't know if I've said moderate before, but I think how we're thinking about initial patients is we're not going into sort of the severe liver disease patients, so we can treat patients with compensated liver disease, and what that means is many of these patients that may have developed cirrhosis, and histologically you see cirrhosis, they've actually compensated for that, and you can see even their fibrous skin score is improving over time. And so those are the types of patients we would treat. We are not going to treat initially decompensated liver disease. That's something we can look to treat later once we've proven out kind of safety in that initial population. So the goal, ultimately, is to go after the full Wilson disease population who have the relevant mutations that we could treat. But I think initially, you know, we'll want to test this in patients that, you know, maybe have some compensated level of liver disease, but again, are not going to be kind of the decompensated cirrhotic.
Got it. Makes sense. So let's shift gears to alpha-1 antitrypsin. And you just got your IND cleared last month, and you're preparing to start the phase one, too. Have you started actually recruiting for the study, and you have line of sight to dose in the first patient? Will you announce that?
Yeah, so we'll announce first patient dose. That's pretty typical of us. And for this program, if you think about the IND, you know, cleared in September, you know, we really typically for these studies, You look to about two to three months, give or take, for first patient dose. So I'd say we're kind of on pace. So, you know, you can expect something, you know, end of the year or soon after as to getting that first patient in if we hit our timelines.
Got it. And on CT.gov, we're not seeing sites listed there. How are you thinking about site selection just with the competitors out there from Beam, Serifa, and CRISPR and Tisara? It may not be a big factor in the dose escalation, but how do you think about that long-term as well?
Yeah, no, it's a great question. I mean, in Wilson, there just isn't a lot of competition, so every site that we go to is very excited to have us come in and enroll our patients. For Alpha 1, it was just a lot more work that kind of went into this ahead of time because there is a lot more competition for these patients and for these sites. But when you're thinking about alpha-1, it's a pretty large population of patients. You know, some estimates have it at at least patients with disease or in augmentation therapy, you know, 8,000 plus. to 10,000 on augmentation therapy in the U.S. In the, you know, ex-U.S., many of these patients are not on augmentation therapy, and so there might even be a bigger pool that you're going to pick from potentially. And so there's a lot of patients out there, and, yeah, there's a lot of companies enrolling, but you're still looking at small ends that they're enrolling. So we're still finding plenty of sites that have patients that we're going to be able to enroll at, But it definitely took some more work to go out there and find the right sites that aren't enrolling for all these other studies.
Got it. Makes sense. And Beam has a development lead in the space, and Sarifa is pointing to AET's levels near 20 micromolar with no expected bystander edits. Does Prime need higher AET levels to differentiate, or could a cleaner editing profile be enough? And if CRISPR or Tessara deliver similar advantages, how would that shape your commercial opportunity?
Yeah, I mean, the way I'm going to answer the question is, we've got to see what everyone's data looks like over time. So I kind of look at the space and say, we've got three companies that are doing prime editing, right? Us, CRISPR, and Tessera. We can talk about the patent infringement if you want in a different question on what's going on there. But you've got three companies doing prime editing. You've got two companies doing base editing. One may have a lower level of bystander edit. At least that's the claim in terms of, like, what levels everyone's getting to. I think we've got to see kind of what that data looks like over time in greater numbers to really assess what each company has. Because, excuse me, I think the safety side is also going to be important. Let's see what everyone's, you know, we have five companies with five different LNPs, right? And let's see what everyone's LNP looks like from a toxicity standpoint if we enroll more patients. So we think we've got a very competitive profile. We think we've got a really good preclinical data package. We're excited to start enrollment and get to our data set. But it's really hard to compare and contrast clinical data when you've got really like three patients here, three patients there. Beam does have the greatest number of patients, and I think they're starting to kind of declare where they're getting to in terms of editing, et cetera, and M levels and M versus Z serum levels. But the other companies are just, you know, too early to really, I'd say, say what levels they're actually getting to when the numbers are that small.
Got it. And you mentioned the patent situation. What do you want to highlight?
No, I mean, I would just highlight that, you know, Prime, you know, any permutation of using a Cas enzyme with a reverse transcriptase, you know, with a peg guide is Prime Editing, right? You can call it whatever name you want to call it, but that's Prime Editing, and Prime exclusively owns the IP to that. There's no other company that owns the foundational IP around Prime Medicine. There's other companies that are doing prime editing and will vigorously enforce our IP estate at the right time.
Got it. Okay. And your study includes a dedicated BRONCOL, the BAL cohort, which what will you measure to establish whether higher circulating AAT translates into functional protection in the lung? And could those data help distinguish your program if CRM-AAT works?
I think other companies are doing that too. I think that's actually something the FDA is asking for these days, to do that as a component of your study. So BAL stands for bronchial alveolar lavage. So they really want to look at what levels of AET look like in that setting just to see if you're getting, not just circulating, but you're getting levels that are actually important in the organ system that you're trying to treat.
Got it, okay. And beyond Wilson's and AETD, Where are you on selecting the next liver indication, and when can we learn the disease setting and timelines?
Yeah, I mean, there are so many... There's interesting opportunities to go in after Wilson and Alpha One. We've been doing a lot of work over the last six months to a year, and there's so many interesting places to go, and we want to make sure the next few indications are ones where we see real opportunity for commercial success, real opportunities where we see real unmet need, and there's some very large indications. So we talk about Wilson and Alpha-1, you're in the sort of tens of thousands. As you start to get, as we go throughout the globally, and as we start to go to other diseases, you're into the hundreds of thousands, or even millions of patients as you're thinking about some of these diseases. And then as we go to smaller diseases, there's some opportunities there too. I think the recent FDA guidance for personalized gene editing potentially opens up opportunities. That can actually help for Wilson's and other indications, but also opportunities where we may not have seen the potential for commercial viability in a sense. The math on that has changed a little bit potentially if this guidance becomes finalized. So we're looking into some of those indications as well where we might see some opportunity.
Got it. And congrats on completing the recent financing. Maybe talk about CGD and your PRV strategy and how you predict financing the company to sustainability.
Yeah, look, we did a capital raise, got some really good investors into the company. As we go forward, we think there's other, call it less equity dilutive ways to bring capital, whether it's business development, whether it's ways to monetize other regulatory vouchers, like you said, BMS milestones, etc. So we think there's a number of ways to fund the company as we look beyond just the recent raise.
Got it. And maybe in closing, highlight key catalysts ahead over the next 6 to 12 months, including competitor readouts that investors should be focused on.
Yeah, I mean, look, we're obviously from a competitor standpoint, you know, there's a trial coming up that's going to look at augmentation therapy. I don't think it has a ton of relevance as we think about gene editing, but for the alpha 1 space, everyone's very focused on it. So I'm actually very interested to see what that data set looks like. From a competitive standpoint, I mean, again, all the five different gene editing and the three or more RNA editing programs, I'm actually very interested to see what all these data sets look like over the next year. But I think importantly for Prime, let's get our CGD program approved. Sometime next year, let's get our Wilson disease and alpha-1 data. Very excited to see that as a big catalyst. Cystic fibrosis, hopefully getting to a drug candidate sometime next year. So a lot of interesting catalysts, important catalysts for the company.
Great. Thanks so much for joining us today, Alan.
All right. Thanks, Maury. Thanks for having us.
0:00 to 25:56 · One card per analyst, follow-ups included. Each plays from its start, and the one being answered is marked.
Hi, everyone. My name is Maury Raycroft, and one of the biotech analysts at Jefferies. I'm happy to introduce and welcome Alan Ryan, the CEO of Prime Medicine. Thanks for joining us today, Alan.
Alan Ryan: Maury, thanks for having us. I appreciate being here.